According to the research report titled ‘Platelet and Plasma Market Size By Component (Platelets, Plasma), By Application, By Distribution Channel (Hospitals, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook, Application Potential, Growth Potential, Price Trend, Competitive Market Share & Forecast, 2020 – 2026’, available with MarketStudyReport, global platelet and plasma market is expected to record a substantial CAGR over the forecast period 2020-2026.
 

As per the report findings, factors such as increasing incidence of chronic diseases, prevalence of liver disorders in the ageing population, technological advancements in therapeutic protein drug development, and fair reimbursement policies in developed countries are propelling global platelet and plasma market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1206946/
 

Moreover, increasing number of blood transfusions, and extensive use of plasma for treating rare diseases are also expected to drive industry expansion in the upcoming years.
 

Notably, blood is made up of several components such as platelets, plasma, red blood cells, and white blood cells. Platelets & plasma are segregated from the blood of a donor and collected, after which the remaining blood and its components are transfused back to the donor. Platelets allow blood to clot, and are administered to patients suffering from leukemia, while plasma, which also promotes blood clotting, is given to treat liver conditions, burns, and severe bacterial infections in blood.
 

Elaborating on the negatives, strict regulatory policies, coupled with affordability issues faced by Latin America and APAC regions due to high technology costs are likely to hamper the remuneration scope of the global platelet and plasma industry over 2020-2026.
 

In terms of application scope, perioperative indications segment accounted for 15% market share in 2019, primarily driven by high requirement for plasma transfusions in order to compensate for the significant amount of blood loss occurring during major invasive surgeries.
 

Based on component type fragmentation of worldwide platelet and plasma industry, plasma segment is slated to register 2% CAGR through 2026, owing to rising demand for treatment of rare chronic conditions such as hemophilia, autoimmune disorders, hereditary angioedema, and other infectious diseases.
 

Considering distribution channel, ambulatory surgical centers segment is set to grow at a CAGR of 2.5% over the assessment timeframe. This can be credited to increasing patient inclination towards these settings owing to the affordability and quality of treatment provided.
 

From a regional frame of reference, Latin America market was valued at USD 460 million in 2019, owing to rising cases of autoimmune disorders, hemophilia, and other infectious diseases in the region.